Royalty Pharma PLC (RPRX) News
Filter RPRX News Items
RPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RPRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RPRX News From Around the Web
Below are the latest news stories about ROYALTY PHARMA PLC that investors may wish to consider to help them evaluate RPRX as an investment opportunity.
Here’s Why Royalty Pharma plc (RPRX) Led This Week’s RallyWe recently published an article titled These 10 Firms Led This Week’s Rally. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against the other stocks. Ten companies finished stronger this week, outpacing the broader market thanks to a series of catalysts that lifted investor sentiment. On Friday, […] |
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?We recently published a list of 10 Firms Close Shortened Trading Week Higher. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against other firms close shortened trading week higher. Wall Street’s main indices ended the shortened trading week in the red territory on Friday after labor […] |
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benefit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s Rytelo NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Ro |
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase ProgramRoyalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of s |
Royalty Pharma Announces Dividend IncreaseNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buy |
Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared some investment wisdom drawn from his four decades of […] |
Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the companyKey Insights Institutions' substantial holdings in Royalty Pharma implies that they have significant influence over the... |
Jim Cramer Calls Royalty Pharma (RPRX) ‘Disappointing’ But Recommends Holding – ‘I Want You To Stick With It’We recently published a list of Jim Cramer’s Latest Portfolio Heading Into 2025: Top 10 Stocks. In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against other stocks in Jim Cramer’s latest portfolio heading into 2025. Jim Cramer in a latest program reiterated his view that the […] |
Royalty Pharma to Present at Upcoming Investor ConferencesNEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ETCiti’s 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. We |
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Royalty Pharma (NASDAQ:RPRX) stands against other cheapest stocks to buy on Robinhood. While the market has been on an upward trajectory for nearly two years now, the combination of seasonal […] |